State well being officers on Wednesday reported lower than 2,000 new COVID-19 circumstances, as Moderna introduced that its new booster candidate “demonstrates superior antibody response against omicron.”
The Massachusetts Department of Public Health on Wednesday reported 1,780 new COVID circumstances, a bit up from final Wednesday’s whole of 1,713 infections. However, testing was 49% increased in comparison with final week.
Omicron subvariants had sparked a latest rise in COVID circumstances, however an infection counts have been declining within the final couple of weeks. The each day common of reported circumstances is now 1,502 infections, a drop from practically 4,000 each day circumstances in mid-May.
The state’s common p.c positivity is now 6.62%, down from 7.72% at the moment final week. The p.c positivity for Wednesday’s report was decrease at 5.19%.
State well being officers on Wednesday reported 16 COVID deaths, bringing the state’s whole recorded demise toll to twenty,709. The each day common of COVID deaths is now eight. The demise price had been a lot increased after omicron hospitalizations surged.
After COVID hospitalizations declined by 18 sufferers, the state’s general affected person rely is now 567 sufferers. Total hospitalizations had been going up after the latest bounce in infections, however hospitalizations dropped within the final couple of weeks.
Across the state, there at the moment are 53 coronavirus sufferers in intensive care items, and 16 sufferers are intubated.
Nearly 5.4 million folks in Massachusetts at the moment are totally vaccinated, and greater than 3 million folks have gotten a booster dose. Also, 517,220 extra booster doses have been administered.
Meanwhile, Cambridge-based Moderna has introduced new scientific information on its omicron-containing bivalent COVID booster candidate. A dose led to an eight-fold enhance in neutralizing antibodies in opposition to omicron.
The shot is Moderna’s lead candidate for a fall 2022 booster.
Moderna CEO Stephane Bancel stated, “We are submitting our preliminary data and analysis to regulators with the hope that the Omicron-containing bivalent booster will be available in the late summer.”
Source: www.bostonherald.com”